BioWorld

Autotelic Bio presents new TGF-β receptor type-1 inhibitors for cancer

Autotelic Bio presents new TGF-β receptor type-1 inhibitors for cancer Oct. 18, 2023 ...
BioWorld

Bisichem Co. Ltd. prepares and tests TGF-β receptor type-1 inhibitors

TGF-β receptor type-1 (TGFBR1; ALK5; SKR4; TβR-I) inhibitors are reported in a recent Bisichem Co. Ltd. patent as potentially useful for the treatment of cancer, obesity, diabetes, fibrosis, ...
EurekAlert!

Exploring the therapeutic potential of TGF-β inhibitors for liver fibrosis: targeting multiple signaling pathways

Schematic representation of different strategies targeting TGF-β signaling for liver fibrosis therapy. TGF-β signaling inhibitors hold important therapeutic potential for hepatic fibrosis. Although ...
ascopubs.org

A phase II double window of opportunity trial evaluating the oral TGF-beta receptor I inhibitor vactosertib in patients undergoing standard of care preoperative therapy for ...

A phase II study of agenT-797 (invariant natural killer T-cells), botensilimab (Fc-enhanced CTLA-4 inhibitor) and balstilimab (anti-PD-1) in patients with advanced, refractory gastroesophageal ...
Business Wire

Bicara Therapeutics’ First-in-class Bifunctional EGFR/TGF-β Inhibitor, BCA101, Demonstrates 65% ORR in Combination with Pembrolizumab in 1L HPV-negative Recurrent/Metastatic ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Bicara Therapeutics, a clinical-stage biotechnology company developing dual-action biologics to elicit a potent and durable immune response, today will present ...
Seeking Alpha

Incyte Corporation (INCY) Discusses ESMO Data on TGF-beta Receptor by PD-1 Bispecific in Colorectal Cancer and G12D Inhibitor in Pancreatic Cancer Transcript

We're going to get started. Thank you, everyone, for joining us here in Berlin, and there are many more of you that are online. Welcome to the solid tumor update that we're having at ESMO 2025. We're ...